Tags

Type your tag names separated by a space and hit enter

Chronobiologic aspects of urinary gonadotropin peptide (UGP).
In Vivo. 1995 Jul-Aug; 9(4):359-62.V

Abstract

When using urinary gonadotropin peptide (UGP) as a marker for ovarian cancer, a circadian rhythm of large amplitude is best assessed for improving preanalytic quality control, for specifying how often and when to sample and for resolving chronobiologic endpoints. In a patient (EH, 73 y) with an ovarian (Müllerian) adenocarcinoma, overall high UGP values occurred consistently around 07:00 (standard deviation, SD = 2 h), similar to the timing observed in a presumably healthy woman. The circadian rhythm of EH averages in amplitude about 45% of the daily mean value (SD = 15%). The results indicate the desirability of deriving time-specified reference limits in health for an improved diagnostic value of UGP. The circadian UGP pattern awaits tests of applications for a chronodiagnosis of ovarian cancer, for optimizing treatment efficacy by timing according to rhythms, and conceivably for detecting earliest precancer risk.

Authors+Show Affiliations

Cornélissen G
University of Minnesota, Minneapolis 55455, USA.
Halberg F
No affiliation info available
Walker R
No affiliation info available
Zaslavskaya RM
No affiliation info available
Fine RL
No affiliation info available
Haus E
No affiliation info available

MeSH

AgedBiomarkers, TumorChorionic Gonadotropin, beta Subunit, HumanChronobiology PhenomenaCircadian RhythmFemaleHumansOvarian NeoplasmsPeptide Fragments

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8555435

Citation

Cornélissen, G, et al. "Chronobiologic Aspects of Urinary Gonadotropin Peptide (UGP)." In Vivo (Athens, Greece), vol. 9, no. 4, 1995, pp. 359-62.
Cornélissen G, Halberg F, Walker R, et al. Chronobiologic aspects of urinary gonadotropin peptide (UGP). In Vivo. 1995;9(4):359-62.
Cornélissen, G., Halberg, F., Walker, R., Zaslavskaya, R. M., Fine, R. L., & Haus, E. (1995). Chronobiologic aspects of urinary gonadotropin peptide (UGP). In Vivo (Athens, Greece), 9(4), 359-62.
Cornélissen G, et al. Chronobiologic Aspects of Urinary Gonadotropin Peptide (UGP). In Vivo. 1995 Jul-Aug;9(4):359-62. PubMed PMID: 8555435.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronobiologic aspects of urinary gonadotropin peptide (UGP). AU - Cornélissen,G, AU - Halberg,F, AU - Walker,R, AU - Zaslavskaya,R M, AU - Fine,R L, AU - Haus,E, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 359 EP - 62 JF - In vivo (Athens, Greece) JO - In Vivo VL - 9 IS - 4 N2 - When using urinary gonadotropin peptide (UGP) as a marker for ovarian cancer, a circadian rhythm of large amplitude is best assessed for improving preanalytic quality control, for specifying how often and when to sample and for resolving chronobiologic endpoints. In a patient (EH, 73 y) with an ovarian (Müllerian) adenocarcinoma, overall high UGP values occurred consistently around 07:00 (standard deviation, SD = 2 h), similar to the timing observed in a presumably healthy woman. The circadian rhythm of EH averages in amplitude about 45% of the daily mean value (SD = 15%). The results indicate the desirability of deriving time-specified reference limits in health for an improved diagnostic value of UGP. The circadian UGP pattern awaits tests of applications for a chronodiagnosis of ovarian cancer, for optimizing treatment efficacy by timing according to rhythms, and conceivably for detecting earliest precancer risk. SN - 0258-851X UR - https://www.unboundmedicine.com/medline/citation/8555435/Chronobiologic_aspects_of_urinary_gonadotropin_peptide__UGP__ DB - PRIME DP - Unbound Medicine ER -